What stage does Delos Capital invest at?

Delos Capital invests at the Seed, Series A, Series B, Series C, Growth, Late Stage stages.

What sectors does Delos Capital focus on?

Delos Capital focuses on Biotech, Healthtech, Medical Devices.

Where is Delos Capital located?

Delos Capital is headquartered in Cambridge, US.

Delos Capital

Venture capital

Cambridge · Seed–Late Stage · 12 people tracked

Also known as DELOS ADVISORS LIMITED · DELOS ADVISORS, INC. · DELOS WEALTH ADVISORS, LLC

★ Follow + Add to CRM ⤳ Find an introduction

✨ Fox Verdict

Investment thesis

Delos Capital invests in life sciences companies working to address disease and improve patient health. The firm seeks out exceptional science paired with strong founding teams pursuing medical breakthroughs. Drawing on a diverse skill set and a global network, the team supports ground-breaking innovations intended to improve lives worldwide.

Invests inBiotech Healthtech Medical DevicesCambridgeChinaGeorge TownGlobalUnited States

Source: firm website, verified Aug 11, 2026.

Stage

Seed–Late Stage

Cambridge, Massachusetts, US

Instruments

Equity

Founded

2014

AUM

$185.6M

VC funds

Tracked investments

Team · 12 people

from the firm's website & public directories

Henry Chen· Managing Partner· Hong Kongin

Henry Chen founded Delos Capital in 2014 and serves as its Managing Partner. He was previously a Partner and Co-Head of Asia at Permira, and earlier spent nine years at Goldman Sachs as a Managing Director and co-head of the General Industrials Group for Asia (ex-Japan), following corporate finance law work at Davis Polk. He has co-founded Curamir Therapeutics and Tulavi Therapeutics and served as CEO and Chairman of Tanvex BioPharma, and holds bachelor's and master's degrees from Harvard University and a JD from Harvard Law School.

h•••@deloscapital.comreveal

Tim Xiao· Partner· Hong Kongin

Partner and founding member of Delos Capital with 16 years in life science advisory and investing; leads investments and sits on or observes boards of numerous biotech and medtech companies. Previously spent seven years in investment banking, most recently at Goldman Sachs.

t•••@deloscapital.comreveal

Eric Huang· Partner, Ph.D.· Boston, Massachusetts, United Statesin

Eric Huang joined Delos Capital as a Senior Advisor in 2020, became an Operating Partner, and transitioned to full-time Partner in 2024. He previously held leadership roles at Moderna Therapeutics, including founding CSO of New Venture Labs, where he conceived the mRNA vaccine platform, and later served as GM and CSO at Moderna Genomics.

e•••@deloscapital.comreveal

Lee Cooper· Managing Director· Cambridge, Massachusettsin

Lee Cooper joined Delos Capital as a Managing Director in 2024, focused on advancing new medicines. He previously invested with Leaps by Bayer, founded a rare-disease genomic diagnostics company as an EIR at RA Capital, and worked on transactions at Moderna Therapeutics. He also lectures on bio-innovation at Tufts and Dartmouth.

l•••@deloscapital.comreveal

Tej Pavoor· Partner· Cambridge, USin

Tej Pavoor joined Delos Capital as a Partner in 2024, focusing on identifying and evaluating life sciences companies. He previously was an Operating Partner at Flagship Pioneering, served as COO of Laronde (now Sail), and spent nearly seven years at Moderna Therapeutics, concluding as SVP overseeing the clinical portfolio; earlier roles included McKinsey and Merck.

t•••@deloscapital.comreveal

Agnes Kwok· Financial Controller· Hong Kongin

Agnes Kwok is the Financial Controller at Delos Capital, based in Hong Kong, where she handles accounting, tax, reporting, and compliance since joining in 2018. She previously worked as Vice President in the Finance and Corporate Tax team at Bank of America Merrill Lynch for eight years and began her career at Ernst & Young focusing on banking, financial services, and asset management. She holds a BBA (Hons) in Accountancy from City University of Hong Kong and is a HK Certified Public Accountant and a member of The Institute of Chartered Accountants in England and Wales.

Andrea Lok· Executive Assistant· Hong Kongin

Andrea Lok joined Delos Capital in 2022 as the Executive Assistant for the firm's Hong Kong office. She previously worked as a secretary in the Corporate Legal Department at Nan Fung Group. She holds a Bachelor's in English for Professional Communications from City University of Hong Kong.

Carrie Greenaway· Office Operations, Boston Office· Bostonin

Carrie Greenaway joined Delos Capital in June 2024 and manages office operations for the firm's Boston office. She has over 15 years of operations experience spanning small startups to venture capital, most recently serving as Director of Finance and Operations at a Santa Monica-based event technology company. She holds a B.A. in International Relations from Saint Anselm College.

Paul Shen· Operations Manager· New Taipei City, New Taipei City, Taiwanin

Paul Shen joined Delos in 2022 as an Operations Manager. Before that, he spent 16 years working as an instructor and educator at five secondary schools and various test preparation centers. He holds a Bachelor of Arts from National Chung Hsing University and completed law extension courses at National Taiwan University.

Wynne Chan· Office Manager, Hong Kong Office· Hong Kongin

Wynne Chan is the Office Manager for Delos Capital's Hong Kong office, a role she has held since joining the firm in 2015. Before Delos Capital, she spent six years as Office Manager/Executive Assistant at Permira Advisers Limited and 14 years as an Executive Secretary in the Investment Banking Division of Goldman Sachs (Asia).

Hank Huang· Associate

h•••@deloscapital.comreveal

Yang Cheng· Associate, Ph.D.· Hong Kong, Hong Kong SARin

Yang Cheng joined Delos in 2022 as an Associate, bringing over ten years of experience in biomedical sciences. She was previously a drug discovery researcher at Boehringer Ingelheim focused on autoimmune diseases, holds a Ph.D. in Genetics from the University of Rochester, and a B.S. in Biology from Xiamen University.

y•••@deloscapital.comreveal

What they invest in

from 20 of 36 portfolio companies

Biotech ×14Healthtech ×12Medical Devices ×10Deep Tech ×3Hardware ×2Advanced Manufacturing ×1AI & Machine Learning ×1Digital Health ×1

HQs:United States×16Canada×1

Investments · 36 tracked

founders shown can be your intro path

By year:2021 · 1 2020 · 1 2019 · 24 dated

Zenas Biopharmazenasbio.cominNASDAQ: ZBIO

BiotechWaltham, US

JOSEPH FARMER(Executive Officer)PATRICK GERALD ENRIGHT(Director)HONGBO LU(Director)TOMAS KISELAK(Director)LEON O. MOULDER, JR.(Director)JOHN JACOB ORLOFF(Director)

Tulavi Therapeuticstulavi.comin✓ verified

Tulavi develops medical devices for peripheral nerve surgery, aiming to improve surgical treatment options and patient outcomes in nerve care.

HardwareHealthtechMedical DevicesMountain View, US

Corinne Bright(Executive Officer, Director)Farhad Khosravi(Executive Officer, Director)Fred Khosravi(Chairman & Co-Founder)Josh Vose(Chief Executive Officer)

BoardHenry Chen(Director)

Verge Medical Aorto-ostial interventional technologiesostialflash.com✓ verified

Verge Medical (formerly Ostial Corporation) develops medical devices for aorto-ostial vascular interventions, including the FLASH Flex aorto-ostial angioplasty system and the RoVo mechanical thrombectomy device, used by physicians for coronary and peripheral vascular cases.

HealthtechMedical Devices

Mike Buck(Chief Executive Officer)Adam Tschida(General Manager & COO)

▶︎ STRM.BIOstrm.bioin

Allecra Therapeutics GmbHallecra.com

Alpha-9 Oncologya9oncology.comin

Alpha-9 Oncology develops radiopharmaceuticals for cancer treatment, with a portfolio of molecules in clinical and preclinical development.

BiotechDigital HealthMedical DevicesVancouver, CA

François Bénard(MD)Kuo-Shyan Lin(PhD)David Perrin(PhD)

AltruBioaltrubio.com

AltruBio develops antibody-based therapeutics for immunological and inflammatory diseases, with clinical-stage candidates (ALTB-268 and ALTB-168) targeting conditions such as ulcerative colitis, psoriatic arthritis, psoriasis, and acute graft versus host disease.

BiotechHealthtech

Antios

Novel antiviral therapies with a lead program in HBV

Apama

Ablation catheter for the untreated atrial fibrillation market (acquired)

Apbioincapbioinc.com

Atia Accommodating intraocular lens replacementatiavision.comin

Atia Vision develops OmniVu, a modular shape-changing dual-optic intraocular lens (IOL) that uses the eye's natural accommodative mechanism to restore near, intermediate, and distance vision for cataract patients.

HardwareHealthtechMedical DevicesCampbell, US

Avenzotxavenzotx.comin

Avenzo Therapeutics is a clinical-stage biopharmaceutical company developing therapeutic treatments.

Biotech

Athena Countouriotis(Co-Founder, Chief Executive Officer)

Avernatxavernatx.comin

Averna Therapeutics develops non-viral gene delivery technology using lipid nanoparticles and engineered retrotransposons to safely insert genetic instructions into cells.

BiotechDeep TechMedical Devices

Baronova

Non-surgical, non-pharmacologic devices to induce weight loss

Cardurioncardurion.comin

Cardurion develops novel cardiovascular therapeutics targeting unmet needs in heart failure and rare arrhythmias through PDE9 and CaMKII inhibition.

BiotechHealthtechMedical DevicesBurlington, US

Cloverbiopharmacloverbiopharma.comin 𝕏

Clover Biopharma is a commercial-stage biotechnology company that develops vaccines using its Trimer-Tag technology platform along with in-house manufacturing and commercial capabilities.

BiotechHealthtech

Curamir TherapeuticsAug 2019

Woburn, US

LAN BO CHEN(Executive Officer, Director)BRYAN KEANEY(Executive Officer)

BoardHENRY CHEN(Executive Officer, Director)

Curatia Interventional vascular productscuratiamed.com

Curatia Medical develops, manufactures, and sells single-use interventional disposables for cardiac, peripheral, neuro, and pulmonary procedures, serving cardiovascular professionals and OEM customers.

Advanced ManufacturingHealthtechMedical DevicesSunnyvale, US

Eccogeneeccogene.comin

Eccogene is a clinical-stage biopharmaceutical company developing oral small molecule therapeutics for cardiometabolic and inflammatory conditions, including obesity, type 2 diabetes, and liver disease.

BiotechHealthtechCambridge, US

Ensomaensoma.com

Boston, US

Hemocorphemocorp.com

Imperative Care Incimperativecare.comin 𝕏

Innovations for vascular disease treatment including strokes and pulmonary embolisms

HealthtechCampbell, US

Matthew Garrett(Executive Officer)Charles Alpuche(Executive Officer)Scott Elliott(Executive Officer)Farhad Khosravi(Executive Officer, Director)Nick Hopkins(Director)

BoardJames Rogers(Director)

Instylla Incinstylla.comin 𝕏

Instylla develops resorbable liquid embolic agents for interventional radiology and oncology, including the Embrace Hydrogel Embolic System and the Tembo Embolic System used to embolize hypervascular tumors and occlude peripheral blood vessels.

BiotechHealthtechMedical DevicesBedford, US

Amarpreet Sawhney(Executive Officer)Raymond Lareau(Executive Officer)Steven Cagnetta(Executive Officer)Sean Boyle(Chief Executive Officer)

BoardHenry Chen(Director)Tasneem Dohadwala(Director)

Intrinsic Therapeuticsbarricaid.comin 𝕏

Barricaid develops a bone-anchored implant designed to reduce reherniation and reoperation in patients undergoing discectomy for large annular defects.

HealthtechMedical DevicesWoburn, US

Gregory H. Lambrecht(Director)Brian Verrier(Director)Joshua Makower(Director)Carey Hagan(Executive Officer, Director)Kevin Sidow(Director)

BoardRyan Drant(Director)

Liposeuticalsliposeuticals.com

Liposeuticals is a specialty pharmaceuticals company that reformulates sterile injectable drugs using a proprietary platform.

BiotechMedical Devices

Luqa

Specialty pharma in dermatology and aesthetics for the Chinese market (acquired)

Phanestheraphanesthera.com

Phanes Therapeutics is a clinical-stage biotech company developing bispecific antibodies and other biologics for immuno-oncology, with three Phase 2 trials (spevatamig, peluntamig, mavrostobart).

BiotechDeep TechHealthtech

Rejonirejoni.cominSep 2020

Hydrogel product to prevent intrauterine adhesions after uterine surgery

BiotechBedford, US

AMARPREET SAWHNEY(Executive Officer, Director, Promoter)NICK SVENCER(Executive Officer, Director, Promoter)FARHAD KHOSRAVI(Executive Officer, Director, Promoter)

BoardTARA BUTLER(Executive Officer, Director, Promoter)

Reniva

Therapeutic option to treat functional and degenerative mitral diseases

PartnerTim Xiao· led

Rgenta Therapeuticsrgentatx.cominNov 2021

Rgenta Therapeutics develops small molecule RNA modulation therapies through a discovery platform, aiming to create treatment options for patients with unmet medical needs across multiple therapeutic areas.

AI & Machine LearningBiotechDeep TechCambridge, US

Judith Li(Director)Debasish Roychowdhury(Director)Travis Wager(Co-founder, President and CSO)Sun Linghao(Director)Hualin Simon Xi(Executive Officer, Director)Zhiping Weng(Co-founder)

Siriusrnasiriusrna.com

Syndaxsyndax.com

Tanvextanvex.com

ThermalinMay 2019

Developer of next-generation insulin solutions

BiotechWaban, US

Richard Berenson(Executive Officer, Director, Promoter)David C. Sweeney(Director)John Brooks(Mr. Brooks is the Chairman of the Board of Directors.)

BoardTim Xiao(Director)

Truvictruvic.com

visit www.trex.biotrex.bioin

Exits · 1

IPOs and acquisitions across the tracked portfolio

Zenas BiopharmaNASDAQ: ZBIO

Portfolio news

latest coverage across their companies

Venture funding drops in Seattle area as AI boom reshapes startup world – GeekWire

Avenzotx · geekwire.com · Jul 13, 2026

Intrinsic Therapeutics Announces Initial Release of Its Next Generation Barricaid Narrow Anchor Device Designed to Reduce Reherniation After Back Surgery

Intrinsic Therapeutics · prnewswire.com · Mar 4, 2026

Frequently asked questions

What stage does Delos Capital invest at?: Delos Capital invests at the Seed, Series A, Series B, Series C, Growth, Late Stage stages.
What sectors does Delos Capital focus on?: Delos Capital focuses on Biotech, Healthtech, Medical Devices.
Where is Delos Capital located?: Delos Capital is headquartered in Cambridge, US.

Images

Similar investors

Amadeus Capital Partners

Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests from seed to growth stages across artificial intelligence, health, and sustainability-focused technologies.

$50K – $12.7M

B Capital Group

B Capital Group is a global venture capital firm that backs founders from early to late stage, with dedicated stage-based funds and a portfolio spanning technology, healthcare, and energy and resilience sectors.

$10M – $50M

Capricorn Venture Partners

Capricorn Venture Partners is a European investment firm managing several thematic funds across growth capital, healthcare, and cleantech, as well as a combined private/quoted investment vehicle.

$270K – $10.8M

DCVC (Data Collective)

DCVC (Data Collective) is a venture capital firm that backs founders building companies which apply technology to major challenges across areas such as energy, biotech, agriculture, and machine learning.

$5M – $25M

Korea Investment Partners

Korea Investment Partners is a South Korea-based venture capital firm that invests across multiple stages from early-stage startups through growth and buyout transactions, including venture debt and mezzanine financing. The firm operates across venture capital, middle market, and growth equity investment categories.

$973K – $50M